Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 2:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 577–600 of 1,553 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: IBD Clear all
Terminated Phase 2 Interventional Results available

Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Ulcerative Colitis

NCT03616821
View directory record Official record
Conditions
Ulcerative Colitis, IBD
Interventions
Brazikumab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
51
States / cities
Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 42 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)

NCT00724126
View directory record Official record
Conditions
Non-Constipation Irritable Bowel Syndrome
Interventions
Rifaximin, Placebo
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
637 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
88
States / cities
Anniston, Alabama • Birmingham, Alabama • Huntsville, Alabama + 83 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2019 · Synced Oct 23, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders

NCT03266068
View directory record Official record
Conditions
Campylobacter Infections, Irritable Bowel Syndrome
Interventions
DNA Analysis of Blood Sample, Flexible sigmoidoscopy with colonic biopsies, Small bowel and colonic gastrointestinal permeability, Stool sample analysis
Genetic · Procedure · Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 2 Interventional

Humanized Anti-IL-2 Receptor Monoclonal Antibody in Moderate-to-severe Ulcerative Colitis

NCT00073047
View directory record Official record
Conditions
Ulcerative Colitis, Gastrointestinal Disease, Inflammatory Bowel Disease
Interventions
Daclizumab
Drug
Lead sponsor
Facet Biotech
Industry
Eligibility
12 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
30
States / cities
Huntsville, Alabama • Anaheim, California • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2009 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional

Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)

NCT01861249
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
SAR339658
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Mission Hills, California • Miramar, Florida • Winter Park, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2016 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 3 Interventional

A Double Blind Study for the Treatment of Acute Ulcerative Colitis

NCT00350415
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Mesalamine
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
18 Years to 75 Years
Enrollment
772 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
78
States / cities
Alabaster, Alabama • Birmingham, Alabama • Tucson, Arizona + 74 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2013 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional

Urinary Prostaglandin E Metabolite (PGE-M), A Metabolite of Prostaglandin E2 (PGE2): A Novel Biomarker of Crohn's Disease Activity

NCT00496548
View directory record Official record
Conditions
Crohn's Disease
Interventions
Fecal calprotectin, Urinary PGE-M Level
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional

The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

NCT04985968
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Cobitolimod 250 mg, Cobitolimod 500 mg, Placebo
Drug
Lead sponsor
InDex Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
171 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
25
States / cities
Granada Hills, California • Mission Viejo, California • Rancho Cucamonga, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents With Active Ulcerative Colitis

NCT00713310
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Asacol 400 mg
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
5 Years to 17 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
26
States / cities
Birmingham, Alabama • Phoenix, Arizona • Loma Linda, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Oct 23, 2026, 2:41 AM EDT
Recruiting No phase listed Observational

Registry and Biorepository for IBD in Central Texas

NCT04617184
View directory record Official record
Conditions
Crohn Disease, Ulcerative Colitis, Inflammatory Bowel Diseases
Interventions
NO INTERVENTION
Other
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 1Phase 2 Interventional

Study of Mesenchymal Stem Cells for the Treatment of Ileal Pouch Fistula's in Participants With Crohn's Disease

NCT04519684
View directory record Official record
Conditions
Ileal Pouch, Crohn Disease
Interventions
Mesenchymal stem cells, Placebo
Drug · Other
Lead sponsor
Anthony Lembo
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis

NCT05785715
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
NX-13 250mg, NX-13 750mg, NX-13 Placebo
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
11
States / cities
Miami, Florida • Orlando, Florida • Tampa, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 15, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Recruiting Phase 2 Interventional

Duloxetine in Inflammatory Bowel Diseases

NCT07431606
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
Duloxetine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
24 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Remote Study of an Electronic Means to Characterize Bowel Movements in Adult Populations

NCT04182048
View directory record Official record
Conditions
Irritable Bowel Syndrome, Healthy
Interventions
Not listed
Lead sponsor
HealthMode Inc.
Industry
Eligibility
18 Years and older
Enrollment
843 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2022
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 25, 2022 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dietary Treatment of Crohn's Disease

NCT00343642
View directory record Official record
Conditions
Crohn's Disease, Inflammatory Bowel Disease
Interventions
Active fructo-oligosaccharide, Placebo fructo-oligosaccharide, Diet
Drug · Dietary Supplement
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Macon, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 9, 2021 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Not applicable Interventional

Mindfulness-Based Eating in Patients With Irritable Bowel Syndrome

NCT02681666
View directory record Official record
Conditions
Abdominal Pain, Irritable Bowel Syndrome, IBS
Interventions
Dietary intervention, Irritable Bowel Syndrome eating awareness training
Dietary Supplement · Behavioral
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis

NCT00408629
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
adalimumab, placebo
Biological
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
518 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
36
States / cities
Anaheim, California • Wheat Ridge, Colorado • Hamden, Connecticut + 29 more
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Oct 23, 2026, 2:41 AM EDT
Withdrawn Phase 4 Interventional

Study of Response to Zoster Vaccine in Adults with Inflammatory Bowel Disease Treated with Medications

NCT06224270
View directory record Official record
Conditions
Inflammatory Bowel Diseases, IBD
Interventions
Adjuvanted Recombinant Zoster Vaccine (RZV)
Biological
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
19 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Jacksonville, Florida • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Oct 23, 2026, 2:41 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of a Wireless Thermal Capsule Endoscopy to Detect Gastrointestinal Thermal Variance

NCT07033208
View directory record Official record
Conditions
Crohn Disease, Inflammatory Bowel Diseases, Healthy
Interventions
Feasibility to obtain thermal variance measurements using a wireless thermal capsule
Device
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Serine Proteases in Gastrointestinal Function and Irritable Bowel Syndrome (IBS)

NCT01072916
View directory record Official record
Conditions
Colon, Irritable
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2015
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2016 · Synced Oct 23, 2026, 2:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects

NCT03327558
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Apriso 0.375G ER CAP, APRISO 375 mg extended-release capsules
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated May 8, 2018 · Synced Oct 23, 2026, 2:41 AM EDT
Not listed No phase listed Observational

Identification Genetic, Immunologic and Microbial Markers of Hirschsprung Associated Enterocolitis in Children With Hirschsprung Disease

NCT02193685
View directory record Official record
Conditions
Hirschsprung Disease, Enterocolitis
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
1 Day to 17 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2016 · Synced Oct 23, 2026, 2:41 AM EDT
Not yet recruiting No phase listed Observational

Naturopathic Approaches to Ulcerative Colitis

NCT07521904
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Naturopathic medicine
Other
Lead sponsor
National University of Natural Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 23, 2026, 2:41 AM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn's Disease

NCT02596893
View directory record Official record
Conditions
Crohn Disease
Interventions
GED-0301, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
150
States / cities
Huntsville, Alabama • Mesa, Arizona • Phoenix, Arizona + 117 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2019 · Synced Oct 23, 2026, 2:41 AM EDT